Title 31

This chapter shall stand repealed on July 1, 2020. History. — Code 1981, § 31-51-10, enacted by Ga. L. 2015, p. 49, § 4-1/HB 1. CHAPTER 52 TERMINALLY ILL PATIENT’S RIGHT TO TRY INVESTIGATIONAL DRUGS, BIOLOGICAL PRODUCTS, AND DEVICES Sec. 31-52-1. 31-52-2. 31-52-3. 31-52-4. 31-52-…

To the extent permissible under this chapter, any research program developed pursuant to this chapter shall be designed to permit the voluntary enrollment of all individuals under 18 years of age having medication-resistant epilepsies who are residents of this state and who: (1) …

(a) For purposes of this chapter, the board of regents may act through a unit of the University System of Georgia, a nonprofit corporation research institute, or a nonprofit institution of higher education that conducts research, or any combination thereof. (b) Any nonprofit corp…

(a) The board of regents or its authorized agent may designate an FDA approved supplier of low THC oil and collaborate with a desig1011 nated supplier to develop a clinical trial or research study protocol to study the use of low THC oil in the treatment of individuals under 18 y…

(Repealed effective July 1, 2020) Voluntary enrollment; residency. (Repealed effective July 1, 2020) Authorized agents. (Repealed effective July 1, 2020) Suppliers of low THC oil. (Repealed effective July 1, 2020) Public record exempt from disclosure.

All activities undertaken pursuant to this chapter shall be subject to availability of funds appropriated to the board of regents or to any other academic or research institution or otherwise made available for purposes of this chapter. History. — Code 1981, § 31-51-6, enacted by…

(a)(1) Research program participants and their parents, guardian, or legal custodian, employees of the board of regents designated to participate in the research program, program agents and collaborators and their designated employees, and program suppliers of low THC oil and the…

The board of regents may establish fees for program participants in such amounts as are reasonable to offset program costs. History. — Code 1981, § 31-51-8, enacted by Ga. L. 2015, p. 49, § 4-1/HB 1.

The board of regents may adopt such rules and regulations as are reasonable and necessary for purposes of this chapter. History. — Code 1981, § 31-51-9, enacted by Ga. L. 2015, p. 49, § 4-1/HB 1.

This chapter shall be known and may be cited as the ‘‘Georgia Right to Try Act.’’ History. — Code 1981, § 31-52-1, enacted by Ga. L. 2016, p. 345, § 1/HB 34.

(a) This chapter shall not be construed to create a private cause of action against a manufacturer of an investigational drug, biological product, or device or against any other person or entity involved in the care of an eligible patient using an investigational drug, biological…

(a) The General Assembly finds and declares that: (1) The process of approval for investigational drugs, biological products, and devices in the United States protects future patients from premature, ineffective, and unsafe medications and treatments over the long run, but the pr…

As used in this chapter, the term: (1) ‘‘Eligible patient’’ means a person who meets the requirements of Code Section 31-52-4. (2) ‘‘Investigational drug, biological product, or device’’ means a drug, biological product, or device which has successfully completed Phase I of a fed…

In order for a person to be considered an eligible patient to access an investigational drug, biological product, or device pursuant to this chapter, a physician must document in writing that the person: (1) Has a terminal illness; (2) Has, in consultation with the physician, con…

Written informed consent shall, at a minimum, include the following: (1) A description of the currently approved products and treatments for the terminal illness from which the patient suffers; (2) An attestation that the patient concurs with his or her physician in believing tha…

(a) A manufacturer of an investigational drug, biological product, or device may make available and an eligible patient may request access to the manufacturer’s investigational drug, biological product, or device pursuant to this chapter; provided, however, that nothing in this c…

A health benefit plan or governmental agency may provide coverage for the cost of any investigational drug, biological product, or device pursuant to this chapter; provided, however, that nothing in this chapter shall be construed to require a health benefit plan or governmental …

The Georgia Composite Medical Board shall not revoke, suspend, sanction, fail to renew, or take any other action against a physician’s license solely based on such physician’s recommendation, prescription, or treatment of an eligible patient with an investigational drug, biologic…

No official, employee, or agent of the state shall block or attempt to block an eligible patient’s access to an investigational drug, biological product, or device. Counseling, advice, or a recommendation for treatment consistent with medical standards of care shall not be constr…

The General Assembly finds that Georgia faces population and community health challenges. The current health infrastructure must be adapted to adequately integrate state and private resources in a manner that will serve to maximize the state’s goals, including improved access to …

As used in this chapter, the term: (1) ‘‘Director’’ means the director of health strategy and coordination established pursuant to Code Section 31-53-4. (2) ‘‘Office’’ means the Office of Health Strategy and Coordination established pursuant to Code Section 31-53-3. History. — Co…

(a) There is established within the office of the Governor the Office of Health Strategy and Coordination. The objective of the office shall be to strengthen and support the health care infrastructure of the state through interconnecting health functions and sharing resources acr…

(a) There is created the position of director of health strategy and coordination who shall be the chief administrative officer of the office. The Governor shall appoint the director who shall serve at the pleasure of the Governor. (b) The director shall have such education, expe…

(a) The director shall have the power to establish and abolish advisory committees as he or she deems necessary to inform effective strategy development and execution. (b) Membership on an advisory committee shall not constitute public office, and no member shall be disqualified …

(a) The office shall compile reports received from the following boards, commissions, committees, councils, and offices pursuant to each such entity’s respective statutory reporting requirements: (1) The Maternal Mortality Review Committee; (2) The Office of Women’s Health; (3) T…

(a) The General Assembly finds that: (1) Cost of care, diagnostic metrics, care gaps, and best practices are best analyzed with large-scale data; (2) The current data infrastructure must be adapted to adequately integrate state and private resources in a manner that will serve th…

(a) The office shall convene a Georgia Data Access Forum composed of health care stakeholders and experts, including representatives from: (1) The Georgia Health Information Network; (2) Hospital associations; (3) Physician associations; (4) Pharmacy associations; (5) Dental asso…

The purpose of the Georgia Data Access Forum shall be to make recommendations to the office on: (1) Conducting a baseline analysis of the current data base infrastructure; (2) Identifying common goals for the state and stakeholders; (3) Prioritizing desired data base functions; (…

— For article, ‘‘The Aftermath of Baby Doe and the Evolution of Newborn Intensive Care,’’ see 25 Ga. St. U. L. Rev. 835 (2009). For article, ‘‘The Problem of Non-Identity in Valuing Newborn Human Life,’’ see 25 Ga. St. U. L. Rev. 865 (2009). For article, ‘‘Baby Doe: Does It Reall…